Press Releases Solasia Pharma K.K. Deutsche Boerse AG

Equities

9SO

JP3436500007

Market Closed - Deutsche Boerse AG Other stock markets 01:20:00 22/05/2024 am IST			5-day change	1st Jan Change
0.14 ^EUR	0.00%		0.00%	-47.76%

15/05	Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024	CI
04/03	Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin	19/03	AQ
Solasia Announces Launch of Darvias® in Japan	22/22/22	BU
Solasia Pharma K K : Business Overview of Pipeline Products (first six months of the Fiscal Year Ending December 31, 2022)	15/22/15	PU
Solasia Pharma K K : Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (under IFRS)	15/22/15	PU
Solasia Pharma K K : Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)	04/22/04	PU
Solasia acquires episil oral liquid business from Camurus	08/22/08	AQ
Solasia Pharma K K : Announces Capital and Business Alliance with Nippon Kayaku Co., Ltd.	28/22/28	PU
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan	20/22/20	BU
DARVIAS Injection 135mg (generic name: DARINAPARSIN /development code: SP-02) approved in Japan	20/22/20	PU
Solasia Pharma K K : Partner, Isofol announced start of study data analysis of SP-05 (arfolitixorin) phase III AGENT study	25/22/25	PU
Solasia Pharma K K : Announcement of the matters to be resolved at the Ordinary General Meeting of Shareholders (March 24, 2022.)	21/22/21	PU
Solasia Pharma K K : Announces Finance via Issuance of Unsecured Straight Bond and Warrant	14/22/14	PU
Solasia Pharma K K : Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer	24/21/24	PU
Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2021)	10/21/10	PU
Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2021 (under IFRS)	10/21/10	PU
Solasia Announces Revision to Full-Year Earnings Forecast	10/21/10	PU
Solasia Pharma K K : Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2021 (under IFRS)	11/21/11	PU
Solasia Pharma K K : Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2021)	11/21/11	PU
Solasia Pharma K K : Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan	30/21/30	BU
Solasia Pharma K K : Announces Exercise Price Revisions Associated with Series 12 Warrants	30/21/30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Solasia Pharma K.K. Deutsche Boerse AG

Equities

9SO

JP3436500007

Press Releases

Filters